Benchtop Lab Equipment Reports Record Revenues and Earnings
Company Focuses On Growth of Digitally Simplified Bioprocessing
BOHEMIA, NY / ACCESSWIRE / November 16, 2021 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three months ended September 30, 2021.
2022 First Quarter Financial Highlights:
Management Discussion
Helena Santos, Chief Executive Officer of Scientific Industries, stated, “Our strong first quarter performance in the Benchtop Laboratory Equipment Operations reflects continued momentum in our core business and the relevance of the Genie brand products. We had another quarter of double-digit revenue growth while maintaining our gross margins despite increased production costs.”
John Moore, Chairman of Scientific Industries and President of Scientific Bioprocessing, Inc., (“SBI”), said, “We continue to execute on our long-term growth strategy, investing our resources to become the market leader for non-invasive online and real time monitoring for bioprocessing applications.”
2022 First Quarter Financial Review
Net revenues for the three months ended September 30, 2021 increased $835,300, or 41.4% to $2,854,500 from $2,019,200 for the three months ended September 30, 2020, reflecting an increase of $599,600 in net sales of the Benchtop Laboratory Equipment Operations’ Genie brand products, and an increase of $235,700 in net revenues of the Company’s Bioprocessing Systems Operations, primarily due to net sales from its German subsidiary, aquila biolabs GmbH, which was acquired in the fourth quarter of fiscal year 2021. The Company realized a loss from continuing operations before income tax benefit of $1,532,300 for the three months ended September 30, 2021 compared to a loss of $189,200 for the three months ended September 30, 2020, primarily due to increased operating expenses incurred by its Bioprocessing Systems Operations, which included significant amounts for product development, sales and marketing, and non-cash compensation expenses related to stock options, partially offset by the record profits generated by increased sales of the Benchtop Laboratory Equipment Operations.
As a result of the above, the Company reflected a net loss of $1,208,800 (or $(0.19) per share) for the three months ended September 30, 2021 compared to a net loss of $263,300 (or $(0.09) per share) for the three months ended September 30, 2020 based on a weighted average number of shares outstanding of 6,458,143 shares and 2,861,263 shares for the three months ended September 30, 2021 and 2020, respectively.
Conference Call Details
Scientific Industries will conduct a conference call to discuss financial results for first quarter of fiscal 2022 on Monday, November 22, 2021, at 4:30 P.M. ET. Interested parties can access the conference call by dialing (877) 270-2148 or (412) 902-6510 (international). A webcast of the call will be available on the Company’s Investor Relations page at https://www.scientificindustries.com/investor-relations/ or at https://www.webcaster4.com/Webcast/Page/2521/43769.
A replay of the call will be available through November 29, 2021 at (877) 344-7529 or (412) 317-0088 (international), confirmation #10162123, or for 30 days at https://www.scientificindustries.com/investor-relations/.
About Scientific Industries, Inc.
Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries’ products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.
About Scientific Bioprocessing, Inc.
Scientific Bioprocessing, Inc. (“SBI”) is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI’s mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit www.scientificbio.com.
Safe Harbor Statement
Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company’s Securities and Exchange Commission reports, including our annual report on Form 10-K.
Company Contact:
Helena R. Santos
CEO and President
Phone: 631-567-4700
hsantos@scientificindustries.com
info@scientificindustries.com
or
Joe Dorame
Lytham Partners, LLC
Phone: (602) 889-9700
SCND@lythampartners.com
–FINANCIAL TABLES FOLLOW-
| SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED BALANCE SHEETS (UNAUDITED) |
||||||
|
|
30-Sep-21 | 30-Jun-21 | ||||
|
ASSETS
|
||||||
|
|
||||||
|
Cash and Cash Equivalents
|
$ | 5,268,700 | $ | 9,675,200 | ||
|
Investment Securities
|
6,985,800 | 3,744,600 | ||||
|
Other Current Assets
|
5,212,200 | 5,011,300 | ||||
|
Intangibles Assets and Goodwill
|
6,814,300 | 6,953,200 | ||||
|
Other Long Term Assets
|
3,933,300 | 3,622,100 | ||||
|
Total Assets
|
$ | 28,214,300 | $ | 29,006,400 | ||
|
|
||||||
|
|
||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||
|
|
||||||
|
Current Liabilities
|
$ | 1,994,000 | $ | 2,286,800 | ||
|
Long-Term Liabilities
|
492,600 | 494,800 | ||||
|
Shareholders’ Equity
|
25,727,700 | 26,224,800 | ||||
|
Total Shareholders’ Equity & Liabilities
|
$ | 28,214,300 | $ | 29,006,400 | ||
|
|
||||||
| SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) |
||||||
|
|
30-Sep-21 | 30-Sep-20 | ||||
|
Revenues
|
$ | 2,854,500 | $ | 2,019,200 | ||
|
Gross Profit
|
1,513,600 | 1,056,700 | ||||
|
Operating Expenses
|
3,038,000 | 1,257,400 | ||||
|
Loss From Operations
|
(1,524,400 | ) | (200,700) | |||
|
Total Other Income (Expense), Net
|
(7,900 | ) | 11,500 | |||
|
Loss From Continuing Operations Before Income Tax (Benefit)
|
(1,532,300 | ) | (189,200 | |||
|
Income Tax (Benefit), Deferred
|
(322,600 | ) | (35,600) | |||
|
Loss From Continuing Operations
|
(1,209,700 | ) | (153,600) | |||
|
Gain (Loss) From Discontinued Operations, Net of Tax
|
900 | (109,700) | ||||
|
Net Loss
|
(1,208,800 | ) | (263,300) | |||
|
Other Comprehensive Gain
|
36,300 | – | ||||
|
Comprehensive Loss
|
$ | (1,172,500 | ) | $ | (263,300) | |
|
Basic Loss Per Common Share:
|
||||||
|
Continuing Operations
|
$ | (0.19 | ) | $ | (0.05) | |
|
Discontinued Operations
|
$ | – | $ | (0.04) | ||
|
Consolidated Operations
|
$ | (0.19 | ) | $ | (0.09) | |
|
Weighted average number of outstanding shares (basic):
|
6,458,143 | 2,861,263 | ||||
SOURCE: Scientific Industries, Inc.
View source version on accesswire.com:
https://www.accesswire.com/673036/Scientific-Industries-Reports-Financial-Results-for-First-Quarter-of-Fiscal-Year-2022
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…